Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 13/1/2021
SIETES contiene 93213 citas

 
 
<< anterior 21 a 40 de 183 siguiente >>
Presentar resultados
Seleccionar todas
21. Cita con resumen
Anónimo. Pertuzumab. Prescrire 2013;33:816. [Ref.ID 96493]
22.Tiene citas relacionadas Cita con resumen
Gagne JJ, Bykov K, Choudhry NK, Toomey TJ, Connolly JG, Avorn J. Effect of smoking on comparative efficacy of antiplatelet agents: systematic review, meta-analysis, and indirect comparison. BMJ 2013;347:11. [Ref.ID 96346]
23.Tiene citas relacionadas Cita con resumen
Hirschl MM. Smoking status and the effects of antiplatelet drugs. BMJ 2013;347:10. [Ref.ID 96345]
24.Tiene citas relacionadas
Wiviott SD, White HD, Ohman EM, Fox KA, Armstrong PW, Prabhakaran DJ, Hafley G, Lokhnygina Y, Boden WE, Hamm C, Clemmensen P, Nicolau JC, Menozzi A, Ruzylio W, Widimsky P, Oto A, Leiva-Pons J, Pavlides G, Winters KJ, Roe MT, Bhatt DL. Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial. Lancet 2013;382:605-13. [Ref.ID 96025]
25.Tiene citas relacionadas
Swaminathan RV, Feldman DN. TRILOGY ACS: prasugrel of benefit only after angiography?. Lancet 2013;382:580-2. [Ref.ID 96024]
26. Cita con resumen
Mahaffey KW, Wojdyla D, Hankey GJ, White HD, Nessel CC, Piccini JP, Patel MR, Berkowitz SD, Becker RC, Halperin JL, Singer DE, Califf RM, Fox KAA, Breithardt G, Hacke W. Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trial. Ann Intern Med 2013;158:861-8. [Ref.ID 95680]
27. Cita con resumen
Grodstein F, O'Brien J, Kang JH, Dushkes R, Cook NR, Okereke O, Manson JE, Glynn RJ, Buring JE, Gaziano M, Sesso HD. Long-term multivitamin supplementation and cognitive function in men: a randomized trial. Ann Intern Med 2013;159:806-14. [Ref.ID 94654]
28. Cita con resumen
VanderWeele TJ, Knol MJ. Interpretation of subgroup analyses in randomized trials: heterogeneity vesus secondary interventions. Ann Intern Med 2011;154:680-3. [Ref.ID 91284]
29. Cita con resumen
Blaha MJ, Budoff MJ, DeFilippis AP, Blankstein R, Rivera JJ, Agatston A, O'Leary DH, Lima J, Blumenthal RS, Nasir K. Associations between C-reactive protein, coronary artery calcium, and cardiovascular events: implications for the JUPITER population from MESA, a population-based cohort study. Lancet 2011;378:684-92. [Ref.ID 91039]
30. Cita con resumen
Anónimo. Fénofibrate: perturbation de la fonction rénale. Prescrire 2011;31:190. [Ref.ID 90307]
31. Cita con resumen
Sun X, Briel M, Busse JW, You JJ, Akl EA, Mejza F, Bala MM, Bassler D, Mertz D, Diaz-Granados N, Vandvik PO, Malaga G, Srinathan SK, Dahm P, Johnston BC, Alonso-Coello P, Hassouneh B, Truong J, Dattani ND, Walter SD, Heels-Ansdell D, Bhatnagar N, Altman DG, Guyatt GH. The influence of study characteristics on reporting of subgroup analyses in randomised controlled trials: systematic review. BMJ 2011;342:748. [Ref.ID 90277]
32.Tiene citas relacionadas Cita con resumen
Hull RD. Extended-duration venous thromboembolism prophylaxis for medical patients. In response. Ann Intern Med 2010;153:689-90. [Ref.ID 89663]
33.Tiene citas relacionadas Cita con resumen
Carson MP, Kuo Y-H. Extended-duration venous thromboembolism prophylaxis for medical patients. Ann Intern Med 2010;153:689. [Ref.ID 89662]
34.Tiene citas relacionadas Cita con resumen
Nieto JA, Valle R, López-Saez JB. Extended-duration venous thromboembolism prophylaxis for medical patients. Ann Intern Med 2010;153:688-79. [Ref.ID 89661]
35.Tiene citas relacionadas Cita con resumen
Dentali F, Gianni M, Squizzato A. Extended-duration venous thromboembolism prophylaxis for medical patients. Ann Intern Med 2010;153:688. [Ref.ID 89660]
36.Tiene citas relacionadas Cita con resumen
Kent DM, Lindenauer PK. Aggregating and disaggregating patients in clinical trials and their subgroup analyses. Ann Intern Med 2010;153:51-2. [Ref.ID 88833]
37.Tiene citas relacionadas Cita con resumen
Hull RD, Schellong SM, Tapson VF, Monreal M, Samama MM, Nicol P, Turpie AGG, Yusen RD, for the EXCLAIM (Extended Prophylaxis for Venous TromboEmbolism in Acutely Ill Medical Patients With Prolonged Immobilization) study. Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility. A randomized trial. Ann Intern Med 2010;153:8-18. [Ref.ID 88831]
38. Cita con resumen
Ridker PM, Glynn RJ. JUPITER, rosuvastatin, and the European Medicines Agency. Lancet 2010;375:2071. [Ref.ID 88667]
39.Tiene citas relacionadas
Albain KS. Anthracycline-based adjuvant chemotherapy in breast cancer. Author's reply. Lancet 2010;375:1871-2. [Ref.ID 88605]
40.Tiene citas relacionadas
Montemurro F, Aglietta M. Anthracycline-based adjuvant chemotherapy in breast cancer. Lancet 2010;375:1871. [Ref.ID 88604]
Seleccionar todas
 
<< anterior 21 a 40 de 183 siguiente >>